International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

Cyltezo®, First and Only FDA-approved Interchangeable Biosimilar to Humira®, Now Commercially Available in the United States

Boehringer Ingelheim announced earlier this month that Cyltezo® (adalimumab-adbm), a U.S. Food and Drug Administration (FDA)-approved Interchangeable biosimilar to Humira® (adalimumab), is now commercially available in the United States. Cyltezo was initially approved as a biosimilar in 2017 for use in multiple chronic inflammatory diseases. Cyltezo was approved as an Interchangeable biosimilar in 2021, and is available as a prefilled syringe, or as a Cyltezo® Pen autoinjector.

Boehringer Ingelheim A Value Through Innovation

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.


Recent Posts

IPC Joins IFPA to Mark the Tenth Anniversary of the World Health Assembly Resolution on Psoriasis

Focus on Psoriasis: A Report from the 2024 American Academy of Dermatology (AAD) Annual Meeting

Psoriasis in Older Patients: Epidemiology, Clinical Features, and Treatment Discussion

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.